An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology

Journal of Virology

Volumn 85, Issue 12, 2011, Pages 5995-6007

  Sharma, Shalini ^a   Mulik, Sachin ^a   Kumar, Naveen ^b   Suryawanshi, Amol ^a   Rouse, Barry T ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CXCL1 CHEMOKINE; INTERLEUKIN 8; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TG 100572; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DISEASE SEVERITY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; IMMUNOPATHOLOGY; INFLAMMATORY CELL; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CORNEA; FEMALE; HERPESVIRUS 1, HUMAN; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PHENOLS; SRC-FAMILY KINASES; TREATMENT OUTCOME; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 79958112610     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00034-11     Document Type: Article

References (31)

1. Abu-Ghazaleh, R., J. Kabir, H. Jia, M. Lobo, and I. Zachary. 2001. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and antiapoptosis in endothelial cells. Biochem. J. 360:255-264.
2. Ambati, B. K., et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993-997.
3. Biswas, P. S., and B. T. Rouse. 2005. Early events in HSV keratitis-setting the stage for a blinding disease. Microbes Infect. 7:799-810.
4. Bock, F., et al. 2007. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 48:2545-2552.
5. Doukas, J., et al. 2008. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J. Cell. Physiol. 216:29-37.
6. Eliceiri, B. P., et al. 1999. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4:915-924.
7. Eliceiri, B. P., et al. 2002. Src-mediated coupling of focal adhesion kinase to integrin alpha v beta 5 in vascular endothelial growth factor signaling. J. Cell Biol. 157:149-159.
8. Gong, Y., and D. R. Koh. 2010. Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. Cell Tissue Res. 339:437-448.
9. Gorbunova, E. E., I. Gavrilovskaya, T. Pepini, and E. R. Mackow. 2011. VEGFR2 and Src kinase inhibitors suppress ANDV induced endothelial cell permeability. J. Virol. 85:2296-2303.
10. Kim, B., et al. 2004. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes-therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165:2177-2185.
11. Kim, M. P., S. I. Park, S. Kopetz, and G. E. Gallick. 2009. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 335:249-259.
12. Kuka, M., et al. 2010. Src Kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists. PLoS One 5(7):e11491. doi:10.1371/journal.pone.0011491.
13. Kumaraguru, U., and B. T. Rouse. 2000. Application of the intracellular gamma interferon assay to recalculate the potency of CD8 (+) T-cell responses to herpes simplex virus. J. Virol. 74:5709-5711.
14. Kvietys, P. R., and M. Sandig. 2001. Neutrophil diapedesis: paracellular or transcellular? News Physiol. Sci. 16:15-19.
15. McGhee, C. N. J., S. Dean, and H. Danesh-Meyer. 2002. Locally administered ocular corticosteroids-benefits and risks. Drug Safety 25:33-55.
16. Nagy, J. A., A. M. Dvorak, and H. F. Dvorak. 2007. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2:251-275.
17. Natarajan, K., M. S. Rajala, and J. Chodosh. 2003. Corneal IL-8 expression following adenovirus infection is mediated by c-Src activation in human corneal fibroblasts. J. Immunol. 170:6234-6243.
18. Newell, C. K., S. Martin, D. Sendele, C. M. Mercadal, and B. T. Rouse. 1989. Herpes-simplex virus induced stromal keratitis-Role of lymphocyte-T subsets in immunopathology. J. Virol. 63:769-775.
19. Noronha, G., et al. 2007. Discovery of 7-(2,6-dichlorophenyl)-5-methylbenzo 1,2,4 triazin-3-yl-4-(2-pyrrolidin-1-ylethoxy)phenyl amine-a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg. Med. Chem. Lett. 17:602-608.
20. Okutani, D., M. Lodyga, B. Han, and M. Y. Liu. 2006. Src protein tyrosine kinase family and acute inflammatory responses. Am. J. Physiol. Lung Cell. Mol. Physiol. 291:L129-L141.
21. Pereira, S., M. Zhon, A. Mocsai, and C. Lowell. 2001. Resting murine neutrophils express functional alpha(4) integrins that signal through Src family kinases. J. Immunol. 166:4115-4123.
22. Perez-Santonja, J. J., E. Campos-Mollo, M. Lledo-Riquelme, J. Javaloy, and J. L. Alio. 2010. Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am. J. Ophthalmol. 150:519-528.
23. Saravia, M., G. Zapata, P. Ferraiolo, L. Racca, and A. Berra. 2009. Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 247:1409-1416.
24. Scheppke, L., et al. 2008. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J. Clin. Invest. 118:2337-2346.
25. Streilein, J. W., M. R. Dana, and B. R. Ksander. 1997. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol. Today 18:443-449.
26. Suryawanshi, A., et al. 2011. Ocular neovascularization caused by HSV-1 infection results from breakdown of binding between VEGF-A and its soluble receptor. J. Immunol. 186:3653-3665.
27. Suvas, S., A. K. Azkur, B. S. Kim, U. Kumaraguru, and B. T. Rouse. 2004. CD4(+) CD25(+) regulatory T cells control the severity of viral immunoinflammatory lesions. J. Immunol. 172:4123-4132.
28. Trevino, J. G., et al. 2005. Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for anglogenesis. Cancer Res. 65:7214-7222.
29. Weis, S. M., and D. A. Cheresh. 2005. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497-504.
30. Zheng, M., S. Deshpande, S. Lee, N. Ferrara, and B. T. Rouse. 2001. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J. Virol. 75:9828-9835.
31. Zheng, M., M. A. Schwarz, S. J. Lee, U. Kumaraguru, and B. T. Rouse. 2001. Control of stromal keratitis by inhibition of neovascularization. Am. J. Pathol. 159:1021-1029.